Item 5. Other Information
Item 5. Other Information
None
70
Item 6. Exhibits
Incorporated by Reference
Exhibit
Number
Exhibit Description
Form
Date
Number
Filed
Herewith
3.1
Amended and Restated Certificate of Incorporation.
8-K
10/19/2015
3.1
3.2
Certificate of Amendment to Amended and Restated Certificate of Incorporation of CytomX Therapeutics, Inc.
8-K
6/23/2020
3.1
3.3
Amended and Restated Bylaws.
8-K
10/19/2015
3.2
4.1
Reference is made to Exhibits 3.1 through 3.2.
4.2
Specimen Common Stock Certificate
S-1/A
9/28/2015
4.1
10.1
Consulting Agreement effective as of October 1, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy .
X
10.2
Consulting Agreement effective as of September 13, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D.
X
10.3#
Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy.
X
10.4#
Separation Agreement effective as of September 12, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D.
X
10.5#
Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D.
X
10.6
Amendment No 3 to Collaboration and License Agreement, dated May 23, 2014, by and between the Company and Bristol Myers Squibb Company, effective as of October 11, 2022.
X
31.1
Certification of Chief Executive Officer required by Rule 13a-14(a) or Rule 15d-14(a).
X
31.2
Certification of Principal Financial Officer required by Rule 13a-14(a) or Rule 15d-14(a).
X
32.1*
Certification of Chief Executive Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).
X
32.2*
Certification of Principal Financial Officer required by Rule 13a-14(b) or Rule 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. §1350).
X
71
101.INS
Inline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document
X
101.SCH
Inline XBRL Taxonomy Extension Schema Document.
X
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase Document
X
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase Document.
X
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase Document.
X
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase Document.
X
104
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
X
Certain confidential portions of this exhibit have been omitted from this exhibit.
# Indicates management contract or compensatory plan.
* The certifications attached as Exhibit 32.1 and 32.2 that accompany this Quarterly Report on Form 10-Q are not deemed filed with the SEC and are not to be incorporated by reference into any filing of CytomX Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Form 10-Q, irrespective of any general incorporation language contained in such filing.
72
SIGNA TURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CytomX Therapeutics, Inc.
Date: November 8, 2022
By:
/s/ Sean A. McCarthy
Sean A. McCarthy, D. Phil.
Chief Executive Officer and Chairman
(Principal Executive Officer)
Date: November 8, 2022
By:
/s/ Christopher W. Ogden
Christopher W. Ogden
Senior Vice President, Finance and Accounting
(Principal Financial Officer and Principal Accounting Officer)
73